Skip to main content
. Author manuscript; available in PMC: 2020 Sep 1.
Published in final edited form as: J Viral Hepat. 2019 May 26;26(9):1105–1116. doi: 10.1111/jvh.13121

Figure 4: Vδ2-TCR repertoire in CHC patients is not associated with proliferative response to Zoledronate stimulation.

Figure 4:

(A) Comparison of the fraction of Vγ2-J1.2 nucleotype rearrangements among all cloned and sequenced rearrangements representing the Vγ2 TCR repertoire in high-expanded (N=5) and low-expanded (N=5) groups. (B) Proportion of the unique Vγ2-Jγ1.2 clonotypes in the representative Vγ2 TCR repertoire. (C) Fraction of Vγ2-Jγ1.2 chains expressing public Jγ1.2 clonotypes in the representative Vγ2 TCR repertoire. (D) Proportion of unique public Jγ1.2 clonotypes among all unique Vγ2-Jγ1.2 clonotypes representing the diversity of public Jγ1.2 clonotypes. (E) Clonotype abundance for the most common public Jγ1.2 chains in healthy African-American donors. Clonotypes marked by shaded color in bottom panel were public clonotypes identified in the CHC patients included for this study. Each column represents one patient. Dark box and white box indicate a public clonotype is present or absent, respectively, in the sample. Horizontal bar indicates median value. Mann Whitney test was used for the comparisons. ns= not significant.